Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days). Grade III leukocytopenia was observed in 6 (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each. The 1-year and 2-year survival rates for definitively irradiated patients were 59% and 39%, respectively, and for patients with postoperative recurrence 69% and 69%, respectively. High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective method for treating esophageal cancer.
Nemoto
Kenji
K
Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan. knemoto@rad.med.tohoku.ac.jp
Matsushita
Haruo
H
Ogawa
Yoshihiro
Y
Takeda
Ken
K
Takahashi
Chiaki
C
Britton
Keith R
KR
Takai
Yoshihiro
Y
Miyazaki
Shukichi
S
Miyata
Tsuyoshi
T
Yamada
Shogo
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016629:Esophagectomy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010865:Pilot Projects; D011879:Radiotherapy Dosage; D016019:Survival Analysis
D009944:Organoplatinum Compounds; C053989:nedaplatin; D005472:Fluorouracil